GlassScriptPhysician profile
Jonathan P Ungar
NPI 1154664530
$112,539.13
in general payments reported to CMS, 2019-2025
33 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,736 · 2021: $7,118 · 2022: $21K · 2023: $20K · 2024: $4,890 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $8,931 · Travel and Lodging: $5,607 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,739.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,425.00 |
| Food and Beverage | $8,930.68 |
| Travel and Lodging | $5,607.20 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $62,804.45 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $22,268.35 | 2019-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $6,425.69 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $4,554.13 | 2023-2025 | Zoryve |
| Tanabe Pharma America, INC. | $3,625.00 | 2022 | |
| Dermavant Sciences, INC. | $2,770.53 | 2022-2024 | Vtama |
| Lilly USA, LLC | $1,772.74 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Janssen Global Services, LLC | $1,650.00 | 2023 | Tremfya |
| Pfizer INC. | $1,034.28 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $827.07 | 2019-2025 | Siliq |
| Regeneron Healthcare Solutions, INC. | $734.26 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $726.32 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $660.38 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $459.05 | 2019-2025 | |
| Leo Pharma INC. | $422.33 | 2021-2025 | Adbry, Spevigo, Anzupgo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $387.14 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $286.11 | 2019-2025 | |
| Biofrontera INC. | $196.96 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $168.32 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $161.97 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $91.58 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $89.72 | 2022-2025 | Xolair |
| Ucb, INC. | $84.68 | 2019-2024 | Bimzelx |
| Dermira, INC. | $79.16 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $65.57 | 2020-2021 | |
| Amgen INC. | $55.93 | 2023-2024 | Otezla |
| Organon LLC | $28.04 | 2025 | |
| Aclaris Therapeutics, INC. | $21.19 | 2019 | |
| Sandoz INC. | $20.24 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $19.51 | 2023 | Poteligeo |
| Lnhc, INC | $16.69 | 2025 | Zelsuvmi |
| Epi Health, LLC | $16.44 | 2019 | |
| Journey Medical Corporation | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ungar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.